Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

CANCER THERAPIES - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Cancer Therapies in US$ Million by the following Product Segments: Immunotherapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 152 companies including many key and niche players such as Amgen, Inc., AstraZeneca PLC, Bayer Schering Pharma, Biogen Idec Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, Imclone Systems, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Genzyme, GlaxoSmithKline, Janssen Biotech, Inc., Merck KGaA, Novartis AG, OSI Pharmaceuticals, Inc., Pfizer, Sanofi-Aventis, Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1551
Price : $4500
Companies : 152
Pages : 897
Date : October 2011
Market Data Tables : 264
Status: * New Report

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  CANCER THERAPIES (Complete Report) Pages : 897   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.....I-14 $295  
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Immunotherapy.....I-4
Targeted Therapy.....I-4
Hormonal Therapy.....I-4
Chemotherapy.....I-4
  
  2. INDUSTRY OVERVIEW.....II-510 $1000  
   Cancer Therapies: An Outlook.....II-5
US Retains Global Dominance.....II-5
Immunotherapies Lead the Suite, Targeted Therapies to Claim the Top Spot.....II-5
1$100
   Cancer Therapies: A Review.....II-61$100
   Enduring Success of Top Drug Makers Makes Oncology Area More Endearing.....II-7
Table 1: Select Leading Cancer Therapies Worldwide by Revenues: 2006-2010 (includes corresponding Graph/Chart).....II-7
1$350
   Monoclonal Antibodies Open Up a New Era in Cancer Treatment.....II-8
Table 2: Leading Monoclonal Antibodies Worldwide by Revenues: 2009 & 2010.....II-8
1$350
   Biotherapies to Drive Growth in Cancer Therapy Market.....II-9
Biotech Cancer Therapies Yet to Overcome Teething Issues.....II-9
Oncology Drugs – the Leader in the Global Pharma Pipeline.....II-9
1$350
   Table 3: Cancer Therapies Market: Number of Approved/Marketed and Pipeline Drugs by Select Cancer Types as of 2010 (includes corresponding Graph/Chart).....II-10
New Cancer Therapies Appear Over the Horizon.....II-10
1$100
   Late Stage Promising Drugs in Cancer Therapy.....II-11
US Ahead in Approving Cancer Drugs.....II-11
1$100
   FDA-Approved Oncology Drugs in Recent Years (2008-2011).....II-121$100
   New Cancer Drugs Approved by EMA in 2009 and 2010.....II-13
Competition Set to Rise in Cancer Therapy.....II-13
1$350
   Table 4: Leading Companies in the Global Oncology Therapy Market (2010): Percentage Breakdown of Revenues for Roche, Novartis, Amgen, AstraZeneca, sanofi-aventis and Celgene (includes corresponding Graph/Chart).....II-14
Competition Intensifies in the Cancer Biotherapy Segment.....II-14
1$100
  3. TRENDS AND ISSUES.....II-154 $400  
   Innovations in Cancer Drug Delivery: A Key Factor in Product Differentiation.....II-15
Follow-On Indications Flock Oncology Pipeline.....II-15
Personalized Medicine: Gain in Importance.....II-15
Combination Therapy: A Double Whammy Success.....II-15
1$100
   Patent Expiries of Branded Drugs to Trigger Generic Competition.....II-16
Rising Investments Bring in New Troubles for Drug Makers.....II-16
Emerging Challenges in Cancer Drug Development.....II-16
1$100
   Select Drugs Receiving Complete Response Letters from the FDA in 2010.....II-17
Drug Failures – Deterring Prospects of New Therapies.....II-17
1$100
   Failures in Phase III Clinical Trials of Oncology Drugs in 2010.....II-18
Drug Withdrawals Hurt Pharma Companies.....II-18
1$100
  4. MARKET DRIVERS AND RESTRAINTS.....II-199 $900  
   Growth Drivers In a Capsule.....II-19
Rise in Cancer Incidences & Access to Modern Therapeutics Foster Growth.....II-19
Demographics & Lifestyles Raise the Risk of Cancer.....II-19
1$100
   Cancer Prone Sites based on Age.....II-20
Table 5: Population of People Aged More than 65 Years in United States for the years 2000, 2010, and 2020 (includes corresponding Graph/Chart).....II-20
Unmet Needs Leave Scope for Further Research and Development.....II-20
Low Entry Barriers in Cancer Research Encourages Breakthrough Developments.....II-20
1$350
   Increasing Investments by National Health Authorities.....II-21
Efficiency & High Prices Magnetize Manufacturers.....II-21
Supportive Cancer Drugs Contribute to Growth.....II-21
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth.....II-21
1$100
   Molecular Imaging of Cancer: Critical in Improving Patient Outcomes.....II-221$100
   Innovations, Improvements, and Approvals Propel Growth.....II-23
Growth Restraints.....II-23
High Prices of Targeted Therapies Act as a Speed Breaker.....II-23
1$350
   Table 6: Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2008.....II-24
Limited Tumor Specificity and Toxicity.....II-24
Complicated Treatment Protocols: A Major Stumbling Block in Patient
  Compliance.....II-24
1$100
   Reduced Smoking.....II-25
Reimbursement and Coverage Remains a Major Challenge.....II-25
Changes in Reimbursement Policies Influence Market Prospects.....II-25
1$100
   Multiple Drug Resistance.....II-26
Stringent Regulations Delay Market Approval.....II-26
Challenges Encountered in Clinical Trials.....II-26
1$100
   High Development Costs Retracts Manufacturers in Developing Countries.....II-271$100
  5. TARGETED THERAPEUTICS.....II-286 $600  
   Current and Future Analysis.....II-28
Targeted Therapy – An Overview.....II-28
Targeted Therapy: The New Frontier of Cancer Treatment.....II-28
1$100
   List of Select Approved Targeted Therapy Drugs by Indication.....II-29
Select Targeted Anti-Cancer Therapies in Late-Stage (Phase III) Clinical
  Development.....II-29
1$350
   Table 7: Targeted Therapies Market Worldwide (2010): Percentage Breakdown of Targeted Therapeutic Drugs under Various Stages of Development (includes corresponding Graph/Chart).....II-301$350
   Table 8: Molecular Targeted Therapies Worldwide: Percentage Breakdown of Molecular Targeted Therapies under Pipeline by Drug Class as of 2010 (includes corresponding Graph/Chart).....II-31
Types of Targeted Therapy.....II-31
Tyrosine Kinase Inhibitors.....II-31
1$100
   List of Approved Tyrosine Kinase Inhibitors.....II-32
Angiogenesis Inhibitors.....II-32
List of Approved Angiogenesis Inhibitors.....II-32
Proteasome Inhibitors.....II-32
Multi-Targeted Drugs.....II-32
1$100
   Select Approved Multi-Targeted Drugs in Targeted Cancer Therapy.....II-33
Gene Therapy.....II-33
1$100
  6. IMMUNOTHERAPY.....II-346 $600  
   Current and Future Analysis.....II-34
Table 9: Global Market for Immunotherapy (2007 and 2012): Percentage Breakdown of Revenues by Drug Class – Monoclonal Antibodies, Biological Response Modifiers, Vaccines, and Other Immunotherapy Products (includes corresponding Graph/Chart).....II-34
1$350
   Immunotherapy Treatment Strategies.....II-35
Vaccination with Dendritic Cells Pulsed With Tumor Antigens.....II-35
Gene Technique-Based Immunotherapy.....II-35
Inhibiting Tumor-Induced Immunosuppression.....II-35
Immunostimulants.....II-35
Use of Monoclonal Antibodies.....II-35
Immunotoxins.....II-35
Radioimmunotherapy.....II-35
T Cells based Therapy.....II-35
Types of Cancer Immunotherapy Drugs.....II-35
Monoclonal Antibodies.....II-35
1$100
   Select Immunotherapy-based Monoclonal Antibodies Approved for Cancer
  Treatment.....II-36
Vaccines – A Promising Future Area of Cancer Therapeutics.....II-36
Therapeutic Cancer Vaccines: Harnessing the Immune System to Fight Cancer.....II-36
1$100
   Cancer Vaccine Strategies.....II-37
RNA-Loaded Dendritic Cells Cancer Vaccine:.....II-37
Liposomal Vaccine:.....II-37
Vaccine Targeting Pregnancy Hormone:.....II-37
Viral Vector Vaccine:.....II-37
Listeria-Based Vaccine:.....II-37
Telomerase Targeting Vaccine:.....II-37
Cancer Vaccine Makes Debut in the US, Finally.....II-37
1$100
   Approved Therapeutic Cancer Vaccines Worldwide.....II-38
Cancer Vaccine Pipeline Shows Significant Promise.....II-38
1$100
   World Cancer Vaccine Pipeline as of 2011.....II-39
Long-Drawn Journey to Success Offers New Lessons for Drug Makers.....II-39
1$100
  7. HORMONE THERAPY.....II-404 $400  
   Current and Future Analysis.....II-40
Hormonal Therapy – An Overview.....II-40
Hormonal Therapy Strategies.....II-40
Hormone Synthesis Inhibitors.....II-40
1$100
   Aromatase Inhibitors.....II-41
GnRH Analogs.....II-41
Hormone Receptor Antagonists.....II-41
Selective Estrogen Receptor Modulators (SERMs).....II-41
Antiandrogens.....II-41
Hormone Supplementation.....II-41
Progestagens and Androgens.....II-41
Estrogens.....II-41
Somatostatin Analogs.....II-41
Shifting Therapeutic Preferences.....II-41
1$350
   Table 10: Global Market for Antihormonal Therapy (2005 and 2014): Percentage Breakdown of Revenues by Drug Class - LHRH Analogs, Aromatase Inhibitors, Anti-androgens, Anti-estrogens, and Other Hormone Antagonists (includes corresponding Graph/Chart).....II-42
Drug Classes in Hormone Therapy.....II-42
Drugs Used in Hormone Therapy and Their Uses.....II-42
1$100
   Side-Effects Associated with the Use of Various Drugs in Hormone Therapy.....II-431$100
  8. CHEMOTHERAPY.....II-444 $400  
   Current and Future Analysis.....II-44
Chemotherapy – An Overview.....II-44
1$100
   The Chemotherapy Market Space – An Overview.....II-45
Chemotherapy Market Cluttered with Numerous Players.....II-45
1$100
   Chemotherapy Drugs Require Careful Handling.....II-46
Types of Chemotherapy.....II-46
Adjuvant Chemotherapy.....II-46
Combined Modality Chemotherapy.....II-46
Neoadjuvant Chemotherapy.....II-46
Palliative Chemotherapy.....II-46
Chemotherapy Drug Classes.....II-46
Nucleoside Analogues.....II-46
Alkylating Agents.....II-46
Antimetabolites.....II-46
Nitrosoureas.....II-46
Steroid hormones.....II-46
Platinum Containing Compounds.....II-46
Folate antagonists.....II-46
Microtubule-targeting agents.....II-46
Topoisomerase inhibitors.....II-46
1$100
   Risks Associated with Chemotherapy.....II-47
When Chemotherapy Fails .....II-47
1$100
  9. AN OVERVIEW OF CANCERS.....II-4810 $1000  
   Cancer: A Major Health Crisis in the Modern World.....II-48
Table 11: Cancer Causes in Developed and Developing Countries (2010): Percentage Breakdown by Risk Factors – Diet or Nutrition, Infections, Tobacco, and Other Factors (includes corresponding Graph/Chart).....II-48
1$350
   Types of Cancers.....II-49
Prostate Cancer.....II-49
Select FDA-Approved Prostate Cancer Drugs.....II-49
1$100
   Select Prostate Cancer Agents in Mid- & Late-Stage Clinical Development.....II-50
Table 12: Revenues of Select Leading Prostate Cancer Drugs: 2006-2010 (includes corresponding Graph/Chart).....II-50
1$350
   Breast Cancer.....II-51
Select FDA Approved Breast Cancer Drugs.....II-51
1$350
   Table 13: Breast Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-52
Cervical Cancer.....II-52
Colorectal Cancer.....II-52
1$100
   Select FDA-Approved Colorectal Cancer Drugs.....II-53
Table 14: Colorectal Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-53
1$350
   Lung Cancer.....II-54
Select FDA-Approved Non-Small Cell Lung Cancer Drugs.....II-54
1$350
   Table 15: Lung Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-55
Renal Cancer.....II-55
Select FDA-Approved Renal Cell Carcinoma Drugs.....II-55
Skin Cancer.....II-55
1$350
   Table 16: Skin Cancer/Melanoma Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-56
Pancreatic Cancer.....II-56
Table 17: Pancreatic Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-56
1$350
   Non-Hodgkin’s Lymphoma.....II-57
Leukemia.....II-57
Bladder Cancer.....II-57
Table 18: Bladder Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-57
Endometrial Cancer.....II-57
1$350
  10. WORLD CANCER STATISTICS.....II-584 $400  
   Cancer Incidence – Statistics on New Cases.....II-58
Table 19: Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart).....II-58
1$350
   Table 20: Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart).....II-59

Table 21: Cancer Incidence in Upper Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart).....II-59
1$350
   Table 22: Cancer Incidence in Lower Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart).....II-601$350
   Table 23: Cancer Incidence in High Income Countries by Site: 2009 (includes corresponding Graph/Chart).....II-611$100
  11. DRUG APPROVALS AND CLINICAL TRIALS.....II-6223 $2300  
   Merck Receives Approval for EMEND® IV in Canada.....II-62
Sun Pharma Receives FDA Approval for Docefrez.....II-62
Amgen Secures FDA Approval for Denosumab.....II-62
Eisai Receives FDA Approval for Halaven.....II-62
1$100
   Dendreon Corporation Secures FDA Approval for Provenge.....II-63
GlaxoSmithKline Secures Accelerated Approval from FDA for TYKERB.....II-63
Roche Receives European Commission Approval for Herceptin in Metastatic Gastric Cancer
  Treatment.....II-63
Gloucester Pharmaceuticals Receives FDA Approval for Istodax.....II-63
1$100
   YM BioSciences Gains Marketing Approval for Nimotuzumab in Mexico.....II-64
Bristol-Myers and ImClone Receives FDA Approval for Erbitux Labeling
  Revisions.....II-64
Abraxis Receives Approval for Abraxane in Quebec, Canada.....II-64
Genentech Receives FDA Approval for Avastin.....II-64
1$100
   ABRAXANE Gains Marketing Approval in Korea, Australia and Other Countries.....II-65
GlaxoSmithKline's Cervarix Finds Place in UK National Immunization Programme.....II-65
1$100
   Biogen Idec and Elan Commence Clinical Trial of TYSABRI.....II-66
Calistoga Pharmaceuticals Starts Phase I Clinical Trial of CAL-101.....II-66
Progen Pharmaceuticals Continues Phase 1 Development of PG-11047.....II-66
GlaxoSmithKline Receives Conditional EU Approval for Marketing Lapatinib.....II-66
Roche’s Xeloda Gains EU Approval for Use in Colorectal Cancer Treatment.....II-66
1$100
   Genentech Secures FDA Approval for Avastin.....II-67
EU Approves Four Biosimilar Versions of Neupogen.....II-67
Russia Approves Oncophage for Kidney Cancer Treatment.....II-67
Eisai to Start Clinical Testing of MORAb-028.....II-67
Threshold Pharmaceuticals Starts Phase I/II Clinical Trials of TH-302.....II-67
1$100
   AVEO Commences Phase 1b Clinical Study of AV-951 and FOLFOX6.....II-68
GSK’s Tykerb Receives USFDA Approval.....II-68
Seattle Genetics Initiates Phase 1b Clinical Trials of SGN-40 with Gemzar and
  Rituxan.....II-68
S*Bio Initiates Phase I Clinical Trials of SB1518.....II-68
Merck Serono Initiates Phase III Trials of Cladribine.....II-68
1$100
   BioCurex Receives Patent for RECAF Technology Applications.....II-69
Chidamide/HBI-8000 Completes Phase I Clinical Trials in China.....II-69
AVEO Initiates Phase I Trials of AV 299.....II-69
Exelixis Completes Phase I Trials of XL765.....II-69
Infinity Pharmaceuticals Starts Phase I Clinical Trial of IPI-926.....II-69
1$100
   Cell Genesys Terminates its VITAL-1 Phase 3 Trial of GVAX.....II-70
GTx Completes Phase II Clinical Trials of Ostarine.....II-70
Imclone Awaits Approval for Erbitux from US Medicine Regulator.....II-70
Kuhnil and Daiichi Sankyo Initiate Phase II Clinical Trial of Nimotuzumab.....II-70
Peplin Starts Phase III Clinical Trials of PEP005 Gel.....II-70
1$100
   ERBITUX Receives Marketing Approval in Japan.....II-71
Progenics Starts Phase I Clinical Study of PSMA ADC.....II-71
FDA Awards Orphan Drug Designation for the Use of Stem Cell Technology in Bone Marrow
  Transplantations.....II-71
Roche, OSI and Chugai Receive Approval for Tarceva in Japan.....II-71
1$100
   Eisai Receives FDA Approval for ONTAK®.....II-72
Genmab Terminates the Development of HuMax-CD4.....II-72
Teva Pharmaceutical Acquires EU Authorization to Market Neutropenia Drug.....II-72
Novartis’ Everolimus Awaits Approvals from US FDA, Swissmedic, and EMEA.....II-72
Abraxis BioScience, AstraZeneca, and NCCN to Conduct Anti-cancer Drug Studies.....II-72
1$100
   Sanofi-Aventis Receives Japanese Approval for Taxotere® Injection.....II-73
Roche’s Avastin Bags European Approval for Renal Cancer Treatment.....II-73
Roche Announces European Approval of Herceptin.....II-73
GSK’s Hycamtin Obtains FDA Approval.....II-73
1$100
   Avastin Receives European Approval for Breast Cancer Treatment.....II-74
Roche’s Tarceva Obtains European Approval.....II-74
Roche’s NeoRecormon Gains European Approval.....II-74
Northwest Biotherapeutics’ DCVax-Brain Gains Swiss Approval.....II-74
Alfacell’s ONCONASE Receives Orphan Drug Designation from US.....II-74
1$100
   Cougar Biotechnology Commences Phase II Trial of CB7630.....II-75
Lorus Therapeutics Receives Orphan Drug Designation for its LOR-2040.....II-75
Merck Serono Receives EU Approval for mCRC Treatment With Erbitux.....II-75
MGI PHARMA and HELSINN Receive FDA Approval For Aloxi.....II-75
FDA Grants Approval for Sutent, a Kidney and Gastrointestinal Cancer Drug.....II-75
1$100
   Wyeth Pharmaceuticals’ TORISEL Receives FDA Approval.....II-76
Dabur Pharma Acquires FDA Approval for Paclitaxel Injection.....II-76
EUSA’s CAPHOSOL Finds Application in Treating Oral Mucositis.....II-76
European Commission Approves Amgen’s Vectibix for Metastatic Colorectal
  Cancer.....II-76
1$100
   GPC Biotech Starts Phase 2 Trials of Satraplatin plus with Tarceva.....II-77
FDA Approves Vectibix as Treatment for Metastatic Colorectal Cancer.....II-77
FDA Approves IND Indication for CYT-500 of Cytogen.....II-77
FDA Clears Rituxan for New Indications.....II-77
1$100
   Epeius Receives BFAD Approval for Expanded Access Program for Rexin- G.....II-78
BioMedicines Initiates Phase 1b Study of Biomed 101.....II-78
1$100
   Avastin Obtains FDA Approval for Treating Recurrent Colorectal Cancer.....II-79
Genentech’s Herceptin Gains FDA Nod for Treating Early stage Cancer after
  Surgery.....II-79
Epeius Starts Phase I and II Trials of the New Tri-Rex Vaccination Protocol.....II-79
Sonus Begins Phase 1 Clinical Trial of TOCOSOL® Camptothecin.....II-79
Dynavax Begins Phase 1 Clinical Trial of TLR9 agonist Combined with Chemotherapy
  Regimen.....II-79
1$100
   Morphotek’s MORAb-009 Receives Orphan Drug Designation.....II-80
Morphotek’s MORAb-003 Receives Orphan Drug Status from the US FDA.....II-80
Morphotek Grants FDA Approval of the IND for MORAb-009.....II-80
1$100
   MannKind Receives IND Clearance for MKC1106-PP Immunotherapy.....II-81
Pharmexa Initiates Phase II trials of GV 1001.....II-81
Wyeth Pharmaceuticals Declares Discontinuation of Phase III Clinical Trials for
  Temsirolimus.....II-81
1$100
   OXiGENE Announces Clinical Trials of CA4P.....II-82
Glaxo SmithKline’s Hycamtin Gains FDA Approval for Treating Cervical Cancer.....II-82
Cell Genesys Announces the Initiation of Amplified Phase I Trial of CG0070.....II-82
Genentech’s Avastin Receives FDA Approval for Lung Cancer Treatment.....II-82
1$100
   Vorinostat Acquires FDA Approval for Skin Cancer Treatment.....II-83
Callisto Launches the First Clinical Trial of Landmark Discovery, L-Annamycin for
  ALL.....II-83
1$100
   Shanghai Sunway Biotech’s H101 Receives Marketing Approval in China.....II-84
Northwest Biotherapeutics Gains Patent for CXCR4.....II-84
Biocon’s Cancer Drug Initiates Phase II Trials.....II-84
1$100
  12. NEW DRUG DEVELOPMENTS AND LAUNCHES.....II-853 $300  
   Dr Reddy's Laboratories Introduces Peg-Grafeel Injection in India.....II-85
Sanofi-Aventis Introduces Jevtana (cabazitaxel) Injection in the US.....II-85
Natco Pharma Introduces Anastrazole for Breast Cancer in US.....II-85
Dr Reddy's Laboratories Introduces Anastrazole Tablets in US.....II-85
Zynx Health Introduces Zynx OncologyCare.....II-85
1$100
   Ferring Pharmaceuticals Introduces FIRMAGON® in Europe.....II-86
GSK Launches Cervarix in Singapore.....II-86
Abeome Launches New Stem Cell Monoclonal Antibody.....II-86
1$100
   Dabur Pharma Launches a New Drug Delivery System, Nanoxel.....II-87
Epeius Biotechnologies Develops New Targeted Anti-Cancer Drugs.....II-87
Monash University Scientists Develop siRNA for Cancer Treatment.....II-87
Cytogen Introduces SOLTAMOX™, the First Hormonal Breast Cancer Therapy.....II-87
1$100
  13. RECENT INDUSTRY ACTIVITY.....II-8833 $3300  
   BioLineRx Acquires License Rights of BL-7030 from Algen.....II-88
Glenmark Establishes New Manufacturing Plant in Argentina.....II-88
Centella Therapeutics Signs Licensing Agreement with Auckland UniServices.....II-88
Cephalon Enters a Definitive Merger Agreement with Gemin X.....II-88
1$100
   IRX Therapeutics Enters a New Research Collaboration.....II-89
RXi Pharmaceuticals Acquires Apthera.....II-89
Gilead Sciences to Enter into Collaboration with Yale School of Medicine for Cancer
  Therapies.....II-89
Sage Bionetworks Forms Alliance with AstraZeneca.....II-89
1$100
   Amgen Acquires BioVex Group.....II-90
AREVA Inks Cooperative Research Agreement with INSERM.....II-90
Dendreon Secures FDA Approval for New Jersey Manufacturing Facility.....II-90
Celgene Acquires Abraxis BioScience.....II-90
1$100
   HUYA Partners with Quintiles to Co-Develop HBI-8000 Cancer drug (US/China).....II-91
China PharmaHub Signs Agreement with Global Player in Precision Glass
  Technology.....II-91
Immunotope Partners with Midatech Group to Form Syntara.....II-91
ChromoCure Acquires GRG.....II-91
1$100
   Qatar National Cancer Society and SAH Global Sign MoU.....II-92
Neogenix Gains FDA Orphan Drug Designation for Ensituximab.....II-92
ImmunoGen Gains Orphan Drug Status for Lorvotuzumab Mertansine.....II-92
Syngene International Enters Into Agreement with Endo Pharmaceuticals.....II-92
Immunovaccine and Oncothyreon Ink Research Agreement.....II-92
1$100
   OncoGenex Inks Licensing Agreement with Teva Pharmaceutical.....II-93
NanoCarrier Enter into Comprehensive Joint Research Agreement with MEDINET.....II-93
VaxOnco Acquires Intellectual Property Rights for Onyvax-P.....II-93
Novation Pharmaceuticals and Cancer Therapeutics Enter into Collaboration.....II-93
1$100
   Cancer Therapeutics Signs Letter of Intent with NanoTherapies.....II-94
sanofi-aventis Acquires BiPar Sciences.....II-94
IBt Bebig, Rusnanotech and Santis Form Joint Venture for Cancer Treatment.....II-94
Roche Acquires Genentech.....II-94
1$100
   AstraZeneca Enters into Collaboration with Merck.....II-95
Cytopia Merges with YM BioSciences.....II-95
Aveo Pharmaceuticals and Biogen Idec Sign Definitive Agreement.....II-95
Opsona Therapeutics Inks Research and Collaboration Agreement with CSL.....II-95
1$100
   Micromet Signs Agreement with Lonza.....II-96
Clavis Pharma Enters Into Agreement with Clovis Oncology.....II-96
Abraxis Takes Over Platco and Shimoda.....II-96
1$100
   WEHI Collaborates with Abbott and Genentech.....II-97
Novartis Inks a Production Deal with Lonza.....II-97
Roche Takes Over UK-Based Biotech Company, Piramed.....II-97
1$100
   Pfizer Acquires Encysive.....II-98
Eden Biodesign Inks a Marketing Services Deal with Human Genome Sciences.....II-98
FivePrime Join Hands with Pfizer for Cancer and Diabetes Research.....II-98
1$100
   Sanofi-Aventis and Dyax Ink Two Antibody Pacts.....II-99
Pfizer and AVANT Ink a Global Licensing Agreement for CDX-110.....II-99
1$100
   Takeda Inks an Exclusive Partnership Agreement with Amgen.....II-100
Genentech and Roche Ink a Licensing Agreement with Glycart.....II-100
Bristol-Myers Squibb Acquires Kosan Biosciences.....II-100
Nabi Biopharmaceuticals Collaborates with NIAID.....II-100
1$100
   Pfizer to Acquire Serenex.....II-101
Morphotek Signs an Agreement with Pivotal BioSciences.....II-101
GE Healthcare Inks a Three-Year Agreement with Eli Lilly.....II-101
ArQule Signs Two Agreements with Daiichi Sankyo.....II-101
1$100
   Circadian Completely Acquires Vegenics Limited.....II-102
Lpath Inks an Accord with Merck Serono.....II-102
Topex Expands its Distribution Deal with Therapy Remarketing.....II-102
Unibioscreen Inks a Partnership Agreement with Drais Pharmaceuticals.....II-102
Avant Immunotherapeutics Becomes Celldex Therapeutics.....II-102
1$100
   Abraxis Enters into Definitive License Agreements with ProMetic Life
  Sciences.....II-103
Biovest International to Receive US$1.6 Million Funding for Biomedical
  Research.....II-103
Access Completes the Acquisition of Somanta.....II-103
Clinical Data Inks an Agreement to Take Over Avalon Pharmaceuticals.....II-103
1$100
   EUSA Pharma Acquires Cytogen Corporation.....II-104
Oncologic Merges with Triton BioSystems.....II-104
Eli Lilly Takes Over ImClone Systems.....II-104
1$100
   CEL-SCI Establishes a New Manufacturing Unit.....II-105
ZaBeCor Establishes Biothorpe Pharmaceuticals, a New Subsidiary.....II-105
Takara Bio Signs a Research Agreement with a Chinese University.....II-105
Shanghai Roche Expands its MabThera Marketing Activities.....II-105
Merck Completes the Acquisition of Majority Stake in Serono.....II-105
1$100
   Merck Enters into Licensing and Collaboration Agreement With Idera.....II-106
Sanofi-Aventis Inks a Global Licensing Deal with Oxford BioMedica.....II-106
WEHI to Collaborate with Genentech and Roche.....II-106
AstraZeneca Acquires MedImmune.....II-106
1$100
   Antisoma Enters into a Global Accord with Novartis.....II-107
Sanofi-Aventis and Astellas Pharma to Restructure their JV Operations in
  Japan.....II-107
Biomira Amends its Agreements with Merck.....II-107
AstraZeneca Takes Over Canadian Biologics Plant.....II-107
1$100
   Pfizer Acquires Coley Pharmaceutical Group.....II-108
Abraxis Takes Over Watson’s Manufacturing Facility.....II-108
Abraxis Takes Over Pfizer’s Cruce Davila Manufacturing Facility.....II-108
1$100
   Bristol-Myers Squibb Takes Over Adnexus Therapeutics.....II-109
Merck Partners with a Florida-based Research Center.....II-109
Organon Partners with Medarex.....II-109
Genzyme Acquires Bioenvision.....II-109
Genentech Inks a Deal with Seattle Genetics.....II-109
TopoTarget Takes Over Apoxis.....II-109
1$100
   Roche Acquires CuraGen’s Subsidiary.....II-110
GPC Biotech Inks an Agreement with Yakult.....II-110
MediGene Acquires Avidex.....II-110
Sanofi-Aventis Inks an Agreement with Taiho.....II-110
1$100
   Biogen Inks Merger Agreement with Conforma.....II-111
Roche Signs a Merger Agreement with Ventana.....II-111
Roche Takes Over THP to Enhance Its Therapeutic Antibody Profile.....II-111
ImClone Systems and Merck Revise ERBITUX Agreement.....II-111
1$100
   GSK Invests €500 Million in France.....II-112
Amgen Takes Over Avidia.....II-112
Moores Cancer Center Collaborates with Medarex.....II-112
ADITUS Medical Forms an Alliance with IGEA.....II-112
1$100
   Callisto Opens Site For Phase–II Clinical Trials of Atiprimod.....II-113
XOMA Inks an Agreement with Attenuon.....II-113
AstraZeneca Joins Schering to Develop a Novel Breast Cancer Drug.....II-113
Nventa to Procure Hiltonol from Oncovir Incorporated.....II-113
1$100
   MaxCyte and Medinet Sign an Agreement for Immuno- Cell Therapy.....II-114
Receptor Acquires Cancer Vaccine ‘G17DT’ from Aphton.....II-114
1$100
   Enzon Collaborates with Santaris for Joint Development of Novel RNA
  Antagonists.....II-115
Epeius Receives Funding from Lazarex for Rexin-G™ Trials.....II-115
Callisto Inks a Deal with M.D. Anderson Cancer Center.....II-115
1$100
   AstraZeneca Inks an Agreement with Abraxis BioScience.....II-116
diaDexus and BVF Establish CFD Therapeutics.....II-116
Merck Acquires US Rights for Liposome Vaccine.....II-116
1$100
   Genentech Enters Into Alliance with Inotek.....II-117
AstraZeneca Takes Over KuDOS Pharmaceuticals.....II-117
Genzyme Acquires AnorMED.....II-117
1$100
   Genentech Collaborates with Accelerate Brain Cancer Cure.....II-118
Sonus and Schering Enter into a Global Licensing Agreement.....II-118
Abgenix Inks Merger Agreement with Amgen.....II-118
1$100
   AstraZeneca and Astex Enter into an Alliance.....II-119
Pfizer Inks Global License Pact with Coley Pharmaceutical Group.....II-119
1$100
   Genzyme Takes Over ILEX Oncology.....II-120
Genentech and CGI Enter into an Exclusive Agreement.....II-120
1$100
  14. FOCUS ON SELECT PLAYERS.....II-12121 $2100  
   Amgen, Inc. (USA).....II-121
Amgen’s Oncology Pipeline As of 2011.....II-121
1$100
   AstraZeneca PLC (UK).....II-122
AstraZeneca’s Cancer Drugs Under Pipeline as of 2011.....II-122
1$100
   Bayer Schering Pharma (Germany).....II-1231$100
   Bayer’s Oncology Pipeline (As of 2011).....II-124
Biogen Idec Inc (USA).....II-124
Bristol-Myers Squibb Company (USA).....II-124
1$100
   Celgene Corporation (USA).....II-125
Celgene’s Oncology Drug Pipeline (As of 2011).....II-125
Cell Therapeutics, Inc. (USA).....II-125
1$100
   Cell Therapeutics’ Oncology Pipeline (As of 2011).....II-126
Cephalon, Inc. (USA).....II-126
1$100
   Cephalon’s Oncology Pipeline (As of 2011).....II-127
Chugai Pharmaceutical Co., Ltd. (Japan).....II-127
1$100
   Chugai’s Oncology Drug Pipeline (As of 2011).....II-128
Eli Lilly and Company (USA).....II-128
1$100
   Lilly’s Oncology Drug Pipeline as of 2011.....II-1291$100
   Imclone Systems, Inc (USA).....II-130
F. Hoffmann-La Roche Ltd (Switzerland).....II-130
1$100
   Select Mid- and Late- Stage Compounds in Roche’s Oncology Pipeline.....II-1311$100
   Genentech, Inc. (USA).....II-132
Genzyme (USA).....II-132
1$100
   Genzymes’ Oncology Drug Pipeline as of 2011.....II-133
GlaxoSmithKline (UK).....II-133
1$100
   GlaxoSmithKline’s Oncology Pipeline (As of 2011).....II-134
Janssen Biotech, Inc (USA).....II-134
1$100
   Merck KGaA (Germany).....II-135
Merck Serono’s Oncology Pipeline (As of 2011).....II-135
1$100
   Novartis AG (Switzerland).....II-136
Novartis’ Oncology Drug Pipeline (As of 2011).....II-136
1$100
   OSI Pharmaceuticals, Inc. (USA).....II-137
OSI Pharmaceuticals’ Oncology Pipeline Status (As of 2011).....II-137
Pfizer (USA).....II-137
1$100
   Pfizer’s Oncology Drug Pipeline (As of 2011).....II-138
Sanofi-Aventis (France).....II-138
1$100
   Oncology Drug Pipeline of sanofi-aventis as of 2011.....II-139
Seattle Genetics, Inc. (USA).....II-139
1$100
   Seattle’s Cancer Therapy Pipeline as of 2011.....II-140
Takeda Pharmaceutical Company Limited (Japan).....II-140
1$100
   Takeda’s Oncology Pipeline (As of 2011).....II-1411$100
  15. GLOBAL MARKET PERSPECTIVE.....II-14215 $1500  
   Table 24: Global Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1421$350
   Table 25: Global Historic Review for Cancer Therapies by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1431$350
   Table 26: Global 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1441$100
   Analytics by Segment.....II-145
Table 27: Global Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-145
1$350
   Table 28: Global Historic Review for Immunotherapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1461$350
   Table 29: Global 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1471$350
   Table 30: Global Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1481$350
   Table 31: Global Historic Review for Targeted Therapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1491$350
   Table 32: Global 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1501$350
   Table 33: Global Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1511$350
   Table 34: Global Historic Review for Hormone Therapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1521$350
   Table 35: Global 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1531$350
   Table 36: Global Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1541$350
   Table 37: Global Historic Review for Chemotherapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1551$350
   Table 38: Global 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1561$100
  16. THE UNITED STATES.....II-15734 $3400  
   A. Market Analysis.....II-157
Current and Future Analysis.....II-157
Table 39: Sales of Select Leading Cancer Drugs in the US (2009 & 2010) (includes corresponding Graph/Chart).....II-157
1$350
   Recession Hits the Pharma Market, Oncology Area too Succumbs.....II-158
Medicare Restructures its Coverage for Chemotherapy.....II-158
Personalized Care for Cancer Treatment in US.....II-158
1$100
   Drugs in Development in the US – A Recent Past Scenario.....II-159
Chemotherapy Drugs Undergoing Trials for Breast Cancer Treatment in United States
  (as of 2007).....II-159
Hormonal Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United
  States (as of 2007).....II-159
1$100
   Targeted Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United
  States (as of 2007).....II-160
1$100
   Statistical Findings.....II-161
Table 40: US Market for Hospital Cancer Therapies (2004 and 2010): Percentage Breakdown of Revenues by Treatment Type – Surgery, Chemotherapy Drugs, Radiation Therapy, Biotechnology-Based Drugs, and Others (includes corresponding Graph/Chart).....II-161

Table 41: US Demand for Chemotherapy Drugs (2004 and 2010): Percentage Breakdown of Revenues by Drug Class - Alkylating Agents & Related, Antimetabolites & Related, Mitotic Inhibitors, and Others (includes corresponding Graph/Chart).....II-161
1$350
   Table 42: US Market for Multiple Myeloma Therapeutics (2009): Percentage Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals and Others (includes corresponding Graph/Chart).....II-162

Table 43: US Market for Breast Cancer Therapeutics (2010): Percentage Breakdown of Revenues by Segment: Targeted Therapeutics, Cytotoxic Therapeutics, and Hormonal Therapeutics, and (includes corresponding Graph/Chart).....II-162
1$350
   US Cancer Statistics.....II-163
Table 44: New Cancer Cases in the US by Affected Site: 2009 (includes corresponding Graph/Chart).....II-163
2$700
   Table 45: New Cancer Cases in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart).....II-1651$350
   Table 46: New Cancer Cases in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart).....II-1661$100
   Cancer Mortality Statistics.....II-167
Table 47: Cancer Related Deaths in the US By Affected Site: 2009 (includes corresponding Graph/Chart).....II-167
2$700
   Table 48: Cancer Related Deaths in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart).....II-1691$350
   Table 49: Cancer Related Deaths in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart).....II-170
New Drug Approvals.....II-170
2$200
   New Drug Launches.....II-1721$100
   Strategic Corporate Developments.....II-1734$400
   Focus on Select Major Players.....II-17711$1100
   B. Market Analytics.....II-188
Table 50: The US Recent Past, Current & Future Analysis for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-188
1$350
   Table 51: The US Historic Review for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1891$350
   Table 52: The US 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1901$100
  17. JAPAN.....II-1916 $600  
   A. Market Analysis.....II-191
Current and Future Analysis.....II-191
Focus on Select Major Players.....II-191
3$300
   B. Market Analytics.....II-194
Table 53: Japanese Recent Past, Current & Future Analysis for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-194
1$350
   Table 54: Japanese Historic Review for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1951$350
   Table 55: Japanese 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1961$100
  18. EUROPE.....II-19719 $1900  
   A. Market Analysis.....II-197
Current and Future Analysis.....II-197
Regional Perspective.....II-197
1$100
   Advancements in Breast Cancer Treatment in Europe.....II-198
New Formulations that are Under Clinical Trials.....II-198
Drugs Undergoing Trials for Bladder Cancer Treatment in Europe As of
  2006.....II-198
1$100
   European Cancer Statistics.....II-199 1$350
   Table 56: Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart).....II-2001$100
   New Drug Approval.....II-201
New Drug Launch.....II-201
Strategic Corporate Developments.....II-201
3$300
   Focus on Select Major Players.....II-2049$900
   B. Market Analytics.....II-213
Table 57: European Recent Past, Current & Future Analysis for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-213
1$350
   Table 58: European Historic Review for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2141$350
   Table 59: European 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2151$100
  19. REST OF WORLD.....II-21613 $4550  
   A. Market Analysis.....II-216
Current and Future Analysis.....II-216
Regional Market Overview.....II-216
Canada.....II-216
Table 60: Estimated New Cancer Cases by Type/ Site Among Canadian Men: 2010 (includes corresponding Graph/Chart).....II-216
1$350
   Table 61: Estimated New Cancer Cases by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart).....II-217

Table 62: Estimated Cancer Deaths by Type/Site Among Canadian Men: 2010 (includes corresponding Graph/Chart).....II-217
1$350
   Table 63: Estimated Cancer Deaths by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart).....II-218
Asia.....II-218
Cancer Statistics in Asia-Pacific.....II-218
1$350
   Table 64: Cancer Incidence in Asia-Oceania by Site: 2009 (includes corresponding Graph/Chart).....II-219
Australia.....II-219
1$100
   India.....II-220
Korea.....II-220
Malaysia.....II-220
1$100
   Latin America.....II-221
Brazil.....II-221
Mexico.....II-221
Argentina.....II-221
New Drug Approvals.....II-221
1$100
   New Drug Launches.....II-2221$100
   Strategic Corporate Developments.....II-2233$300
   B. Market Analytics.....II-226
Table 65: Rest of World Recent Past, Current & Future Analysis for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-226
1$350
   Table 66: Rest of World Historic Review for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2271$350
   Table 67: Rest of World 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2281$350
COMPETITION 653$995
  
Total Companies Profiled: 152 (including Divisions/Subsidiaries - 168)

Region/Country                 Players


The United States                  96   
Canada                             11
Japan                               8
Europe                             34
     France                         6
     Germany                        4
     The United Kingdom             7
     Spain                          3
     Rest of Europe                14
Asia-Pacific (Excluding Japan)     14
Middle-East                         5
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign